Fujisawa Pharmaceutical Company, Ltd.

Zeria Pharmaceutical Co., Ltd.

Sawai Pharmaceutical Co., Ltd.

Ikuo Ueda

Masaaki Matsuo

Masayuki Kato

Masakazu Kobayashi

Tadashi Kitaguchi

Youichi Shiokawa

Mineo Niwa

Takao Takaya

Hisashi Takasugi

Takashi Manabe

Masanobu Nagano

Yousuke Katsura

Hiroki Ono

Koichi Takimoto

Takashi Masugi

Hiromu Kochi

Yoshinari Sato

Atsushi Akahane

Nobukiyo Konishi

Yoshimasa Saito

Suminori Umio

Daizo Morino

Kiyoshi Tsuji

Susumu Satoh

Yoshinori Ishii

Hisashi Yamada

Shizuo Maeno

Yoshihiko Kitaura

Kiyoshi Taniguchi

Kazuhiko Take

Hiromichi Itani

Susumu Sato

Daizou Morino

Takao Watanabe

Tsutomu Toyonaka Teraji

Hiroshi Matsuda

Hiroshi Imanaka

Osamu Nakaguti

Osamu Nakaguchi

Fumio Shimojo

Shigetaka Nishino

Takatomo Ogahara

Teiji Kishimoto

Hiroyuki Okumura

Katsuo Shinozaki

Takeshi Shogaki

Takao Kakita

Kazuyoshi Jomon

Heihachiro Arai

Katsuyuki Ishii

Chihiro Kusunoki

Tadashi Hitaguchi

Hiromu Toyoda

Masumi Furukawa

Seiichi Nakatsugi

Emi Masai

Tsuyako Yashima

Heiichi Sakai

Junzi Hosoda

Masakazu Kobayshi

Keiji Takai

Yoshiharu Kasai

Yoshimasa Saitoh

Yosiharu Kasai

DNA fragments which contain a sequence of DNA which encodes a protective peptide-fused &agr;-hANP in which the protective peptide has a C-terminus lysine residue which is directly fused to the N-terminus of the &agr;-hANP, vectors which contain such a DNA sequence, and microorganisms transformed which such a vector are useful for the production of &agr;-hANP.

Process for the production of &agr;-human atrial natriuretic polypeptide

1. A compound of the formula: ##STR1## wherein the symbol of a solid line with a broken line means a single bond or a double bond, R and R' are independently selected from the group consisting of hydrogen atom, halogen atom, lower alkyl, nitro, unsubstituted amino and substituted amino, A and B are independently selected from the group consisting of hydrogen atom, lower alkyl optionally substituted with a lower cycloalkyl, aryl optionally substituted with one or more halogen atoms and the group: -Y-R.sup.2 wherein Y is lower alkylene and R.sup.2 is the group: ##STR2## wherein m is integer of 1 to 3, n is 0 or 1, Z is &gt;N-, &gt;CH-- or &gt;C=, R.sup.3 is diaryl (lower) alkyl optionally substituted with one or more halogen atoms or is condensed heterocyclic group optionally substituted with oxo, with the proviso that (a) at least one of A and B is the group -Y-R.sup.2 and (b) when A is hydrogen atom and B is the group -Y-R.sup.2, then Z is &gt;CH-- or &gt;C= if R.sup.3 is condensed heterocyclic group optionally substituted with oxo and n is O or a pharmaceutically acceptable salt thereof. The compounds of the above formula have antiallergic activity.

Carbostyril derivatives and antiallergic agent

Two-cistronic Met-IGF-I expression vector, in which the first cistron encodes a protective peptide with a molecular weight of about 500-50,000 and the second cistron encodes IGF-I, was provided. Also provided is a process for preparing Met-IGF-I, which comprises transforming E. coli with said vector and growing the resultant transformant, followed by the lysis of the cell culture and isolation of Met-IGF-I.

Expression vector for insulin-like growth factor I and method of

Substituted acetamide derivatives, process for their preparation and

Indoleacetic acid derivatives, process for their preparation, and

The cysteine-containing polypeptide is oxidized with hydrogen peroxide to produce the biologically active polypeptide having the intramolecular disulfide bridge.

Process for the formation of intramolecular disulfide bridge in a

IGF-I fused with a protective peptide, in which the protective peptide is a protein peptide and is used for the protection of IGF-I from degradation by protease in cells of E. coli is disclosed. Also disclosed are genes coding for the fused IGF-I's, plasmids containing the genes, and E. coli microorganisms transformed with the plasmids.

IGF-I fusion proteins; protection of IGF-I from degradation by host

IGF-I fusion proteins; protection of IGF-I from degradation by host cell

The present invention relates to N-containing fused heterocyclic compounds of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are each hydrogen, halogen, aryl, lower alkyl, halo (lower) alkyl or nitro,

Piperazine compounds and antithrombotic pharmaceutical composition

The present invention relates to imidazopyridine compounds of the formula: ##STR1## wherein R.sup.1 is lower alkynyl or lower alkynyloxy(lower)-alkyl,

Imidazopyridine compounds useful in the treatment of ulcers

This invention provides a benezene-fused heterocyclic compound of the formula: ##STR1## wherein R.sup.1 is halogen, nitro, amino, hydroxy, lower alkyl, lower alkoxy substituted by carboxy or protected carboxy, acylamino which may have lower alkyl on the amino moiety, or aryloxy which may have halogen,

Benzene-fused heterocyclic compound and their use as diuretics

This invention provides a oxothiazolidine compound of the formula: ##STR1## wherein R.sup.1 is acyl;

Oxothiazolidine compound and composition containing same

The present invention relates to a .sup.59 Valine insulin-like growth factor I (.sup.59 Val.IGF-I), to a .sup.59 Val-IGF-I fused to a protective peptide, to a gene coding for .sup.59 Val-IGF-I, to a gene coding for fused .sup.59 Val-IGF-I, to a plasmid containing the .sup.59 Val-IGF-I gene, to a host organism containing a plasmid containing the .sup.59 Val-IGF-I gene, to a host organism containing a plasmid containing the fused .sup.59 Val-IGF-I gene, and to processes for the production of these.

.sup.59 Valine insulin-like growth factor I and process for production

A thiazole compound of allergically activity of the formula: ##STR1## wherein R.sup.1 is amino optionally having suitable substituent(s),

Antiallergic thiazole compounds

A compound of the formula: ##STR1## wherein R.sup.1 is lower alkyl,

Imidazoisoquinoline compounds useful as anti-ulcerative agents

Growing community of inventors

Toyonaka, Japan

Ikuo Ueda